A New CDx for NSCLC is here. The VENTANA PD-L1 (SP263) Assay is now FDA approved.
The VENTANA PD-L1 (SP263) Assay is an FDA-approved CDx that enables your lab to identify NSCLC patients eligible for treatment with TECENTRIQ (atezolizumab) in early stage NSCLC
VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody Class I
PD-L1 is an informative immunotherapy biomarker: Aberrant expression of PD-L1 on tumor and immune cells
in the tumor microenvironment impedes anti-tumor immunity, allowing tumors to grow and metastasize.
Broad Tissue Application
Aids in PD-L1 Expression for Many Tumor Types
The VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody is intended for laboratory use in the PD-L1 protein in the formalin-fixed, paraffin-embedded tissue. It is intended to be used on the BenchMark Ultra. It is indicated as an aid in the assessment of PD-L1 expression in human tissues.
*In the US only available on the BenchMark ULTRA Instrument
VENTANA PD-L1 (SP263) Rabbit Monoclonal Antibody
Material Number: 07494190001
Part Number: 790-4905
Research Use Only
Learn More about the RUO PD-L1 (SP263) Image Analysis Algorithm
RUO: SP263 Image Analysis Algorithm Video
Intro to uPath PD-L1 SP263 Image Analysis Algorithm